BioStock Studio: CLS on a Q3 characterised by US-advancement

Medtech Clinical Laserthermia Systems, CLS, can look back on a third quarter characterised by advancement on the US market. In September, the company received FDA clearance for the use of CLS system for laser ablation in neurosurgery, and the US commercialisation is now initiated. CEO Dan Mogren visited BioStock’s studio to talk about the past quarter.

Read the article at biostock.se:

https://www.biostock.se/en/2022/11/cls-on-a-q3-characterised-of-us-advancement/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/en/